0001387131-23-006024.txt : 20230504 0001387131-23-006024.hdr.sgml : 20230504 20230504075349 ACCESSION NUMBER: 0001387131-23-006024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230504 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 23886582 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_050423.htm CURRENT REPORT
0001430306 false 0001430306 2023-05-04 2023-05-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): May 4, 2023

 

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction 

of Incorporation) 

(Commission 

File Number)

(IRS Employer 

Identification No.) 

 

 26 Main Street, Chatham, New Jersey 07928 

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 
 

 

Item 7.01.Regulation FD Disclosure.

 

On May 4, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) cleared an Investigational New Drug (“IND”) application to support a Phase 1 clinical trial of the Company’s TNX-1500 (anti-CD40L monoclonal antibody [mAb]) product candidate for the prevention of organ rejection in patients receiving a kidney transplant. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

On May 4, 2023, the Company announced that the FDA cleared an IND application to support a Phase 1 clinical trial of TNX-1500 for the prevention of organ rejection in patients receiving a kidney transplant. The Company expects to initiate enrollment in the Phase 1 study in the third quarter of 2023. The Company’s primary focus of early development will be allotransplantation in which the donor organ comes from another human, with potential development of TNX-1500 for xenograft transplantation in which the donor organ comes from a genetically engineered pig, as well as additional indications. The IND application for TNX-1500 was supported by preclinical allotransplantation studies conducted at Massachusetts General Hospital (“MGH”), led by principal investigators Tatsuo Kawai, MD, Professor of Surgery, Harvard Medical School, and Richard Pierson, MD, Professor of Surgery at MGH and director of the Center for Transplantation Science.

 

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

 

Item 9.01.Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press Release of the Company, dated May 4, 2023

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 
 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: May 4, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE OF THE COMPANY, DATED MAY 4, 2023
 

Tonix Pharmaceuticals Holding Corp. 8-K

Exhibit 99.01

 

Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant

Multiple Additional Indications Possible, Including Autoimmune Diseases: Pipeline within a Product

Published Non-Human Primate Studies Show TNX-1500 Prolongs Renal and Heart Allograft Survival

Phase 1 Clinical Trial of TNX-1500 Expected to Start Third Quarter 2023

CHATHAM, N.J., May 4, 2023 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 1 clinical trial with TNX-1500 (anti-CD40L monoclonal antibody [mAb]). The first indication Tonix is seeking for TNX-1500 is the prevention of organ rejection in patients receiving a kidney transplant. The Company expects to initiate enrollment in the Phase 1 study in the third quarter of 2023.

The IND application for TNX-1500 was supported by preclinical allotransplantation studies conducted at the Massachusetts General Hospital (MGH), led by principal investigators Tatsuo Kawai, MD, PhD, A. Benedict Cosimi Chair in Transplant Surgery, MGH and Professor of Surgery, Harvard Medical School (HMS), and Richard N. Pierson III, M.D., scientific director of the Center for Transplantation Sciences in the Department of Surgery at MGH and Professor of Surgery at HMS.

“This is an important milestone as we advance TNX-1500 into clinical development,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection. Our primary focus of early development will be allotransplantation in which the donor organ comes from another human. However, in the longer term we hope to develop TNX-1500 for xenograft transplantation in which the donor organ comes from a genetically engineered pig.”

Dr. Lederman continued, “We view TNX-1500 as a pipeline within a product, because of its potential to treat a number of autoimmune diseases. Anti-CD40L mAbs have demonstrated activity and tolerability in autoimmune diseases like systemic lupus erythematosus and Sjögren’s Syndrome. An anti-CD40L mAb is also in development for multiple sclerosis. CD40L is a member of the TNFα super gene family. Other TNFα super gene members have been the targets of successful mAb therapeutics: TNFα and RANKL for autoimmune diseases and osteoporosis, respectively. Still other TNFα super gene family members are targeted by mAbs in development including TNF-like ligand 1A (TL1A) and CD30L for ulcerative colitis and Ox40L for atopic dermatitis.”

 
 

 

TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease FcγRIIA binding and to therefore reduce the potential for thrombosis. Preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft organ rejection and was well tolerated1,2.

About TNX-1500

TNX-1500 (Fc-modified anti-CD40L mAb) is a humanized monoclonal antibody that interacts with the CD40-ligand (CD40L), which is also known as CD154. TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the treatment of autoimmune diseases and for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT). A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Two articles have recently published in the American Journal of Transplantation that demonstrate TNX-1500 prolongs non-human primate renal and heart allograft survival1,2.

1Lassiter, G., et al. (2023). TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs non-human primate renal allograft survival. American Journal of Transplantation. April 3, 2023. https://doi.org/10.1016/j.ajt.2023.03.022

 

2Miura, S., et al. (2023) TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs non-human primate cardiac allograft survival. American Journal of Transplantation. April 6, 2023. https://doi.org/10.1016/j.ajt.2023.03.025

 

Tonix Pharmaceuticals Holding Corp.*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets), a once-daily formulation being developed as a treatment for major depressive disorder (MDD), is also currently enrolling with interim data expected in the fourth quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox, for which a Phase 1 study is expected to be initiated in the second half of 2023. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease portfolio also includes TNX-3900 and TNX-4000, classes of broad-spectrum small molecule oral antivirals.

 

 
 

 

*All of Tonix’s product candidates are investigational new drugs (IND) or biologics and have not been approved for any indication. TNX-801, TNX-2900, TNX-3900 and TNX-4000 are in pre-IND stage of development and have not been approved for any indication.

 

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

 

Contacts

Jessica Morris (corporate)

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Maddie Stabinski (media)

Russo Partners

Madeline.Stabinski@russopartnersllc.com

(212) 845-4273

 

Peter Vozzo (investors)

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

 

 

 

 

 EX-101.SCH 3 tnxp-20230504.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20230504_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20230504_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 04, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tnxp-8k_050423_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-05-04 2023-05-04 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 2023-05-04 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY M%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:< MW@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I! MK-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H M%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.L ML8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( +@^I%8D'INBK0 M /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2 MY0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D M1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " "X/J1699!Y MDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE M+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WU MV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R M;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@ M9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M! M3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ M 0(4 Q0 ( +@^I%8'04UB@0 +$ 0 " 0 !D M;V-0&UL4$L! A0#% @ N#ZD5I']#/SO *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ MN#ZD5IE&PO=V]R:W-H965T&UL4$L! A0#% @ MN#ZD5I^@&_"Q @ X@P T ( !APP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ N#ZD M5B0>FZ*M ^ $ !H ( !K!$ 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !D1( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ ) @ VQ, end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-8k_050423.htm ex99-01.htm tnxp-20230504.xsd tnxp-20230504_lab.xml tnxp-20230504_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tnxp-8k_050423.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tnxp-8k_050423.htm" ] }, "labelLink": { "local": [ "tnxp-20230504_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20230504_pre.xml" ] }, "schema": { "local": [ "tnxp-20230504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20230504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tnxp-8k_050423.htm", "contextRef": "From2023-05-04to2023-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://tonixpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tnxp-8k_050423.htm", "contextRef": "From2023-05-04to2023-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://tonixpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001387131-23-006024-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-006024-xbrl.zip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